Renal risk stratification in systemic
immunoglobulin light-chain (
AL) amyloidosis is according to estimated glomerular filtration rate (eGFR) and urinary
protein creatinine ratio (uPCR), the latter attributed to glomerular dysfunction, with proximal tubular dysfunction (PTD) little studied. Urinary
retinol binding protein 4 (uRBP), a low molecular weight tubular
protein and highly sensitive marker of PTD, was prospectively measured in 285 newly diagnosed, untreated patients with systemic
AL amyloidosis between August 2017 to August 2018. At diagnosis, the uRBP/
creatinine ratio (uRBPCR) correlated with serum
creatinine (r = 0·618, P < 0·0001), uPCR (r = 0·422, P < 0·0001) as well as both fractional excretion of
phosphate and
urate (r = 0·563, P < 0·0001). Log uRBPCR at diagnosis was a strong independent predictor of
end-stage renal disease {hazard ratio [HR] 2·65, [95% confidence interval (CI) 1·06-6·64]; P = 0·038}, particularly in patients with an eGFR >30 ml/min/1.73 m2 [HR 4·11, (95% CI 1·45-11·65); P = 0·008] and those who failed to achieve a deep haematological response to
chemotherapy within 3 months of diagnosis [HR 6·72, (95% CI 1·83-24·74); P = 0·004], and also predicted renal progression [HR 1·91, (95% CI 1·18-3·07); P = 0·008]. Elevated uRBPCR indicates PTD and predicts renal outcomes independently of eGFR, uPCR and clonal response in systemic
AL amyloidosis. The role of uRBPCR as a novel prognostic
biomarker merits further study, particularly in
monoclonal gammopathies of renal significance.